Rapport Therapeutics (RAPP) Financials

Rapport Therapeutics logo
$23.14 -0.62 (-2.62%)
As of 10:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Rapport Therapeutics

Annual Income Statements for Rapport Therapeutics

This table shows Rapport Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-35 -78 -111
Consolidated Net Income / (Loss)
-35 -78 -111
Net Income / (Loss) Continuing Operations
-35 -78 -111
Total Pre-Tax Income
-35 -78 -111
Total Operating Income
-36 -83 -125
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
36 83 125
Selling, General & Admin Expense
8.18 22 30
Research & Development Expense
28 61 95
Total Other Income / (Expense), net
1.40 4.75 14
Interest & Investment Income
2.53 12 14
Basic Earnings per Share
($23.10) ($3.78) ($2.86)
Weighted Average Basic Shares Outstanding
1.51M 20.74M 38.93M
Diluted Earnings per Share
($23.10) ($3.78) ($2.86)
Weighted Average Diluted Shares Outstanding
1.51M 20.74M 38.93M
Weighted Average Basic & Diluted Shares Outstanding
- 36.50M 47.79M

Quarterly Income Statements for Rapport Therapeutics

This table shows Rapport Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 30 - - - 44
Net Income / (Loss) Attributable to Common Shareholders
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Consolidated Net Income / (Loss)
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Net Income / (Loss) Continuing Operations
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Total Pre-Tax Income
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Total Operating Income
-17 -21 -22 -24 -27 -29 -30 -39 -24 -61 -44
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 20 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 20 0.00 0.00
Operating Revenue
- - - - 0.00 0.00 0.00 - 20 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
17 21 22 24 27 29 30 39 44 61 44
Selling, General & Admin Expense
4.59 5.11 6.10 6.32 7.54 6.82 7.71 8.25 11 9.39 9.77
Research & Development Expense
13 16 16 17 20 23 22 30 33 51 34
Total Other Income / (Expense), net
-5.58 2.68 4.10 3.54 3.05 2.76 3.06 4.75 4.36 4.19 3.85
Interest & Investment Income
1.82 2.68 4.10 3.54 3.05 2.76 3.06 4.75 4.36 4.19 3.85
Basic Earnings per Share
($11.07) ($1.70) ($0.50) $9.49 ($0.68) ($0.75) ($0.71) ($0.72) ($0.42) ($1.19) ($0.84)
Weighted Average Basic Shares Outstanding
2.05M 10.67M 34.86M 20.74M 35.27M 35.44M 37.93M 38.93M 47.24M 47.47M 47.77M
Diluted Earnings per Share
($11.07) ($1.70) ($0.50) $9.49 ($0.68) ($0.75) ($0.71) ($0.72) ($0.42) ($1.19) ($0.84)
Weighted Average Diluted Shares Outstanding
2.05M 10.67M 34.86M 20.74M 35.27M 35.44M 37.93M 38.93M 47.24M 47.47M 47.77M
Weighted Average Basic & Diluted Shares Outstanding
- 36.58M 36.58M 36.50M 36.50M 36.50M 47.66M 47.79M 47.83M 47.98M 59.28M

Annual Cash Flow Statements for Rapport Therapeutics

This table details how cash moves in and out of Rapport Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
39 -77 -4.16
Net Cash From Operating Activities
-27 -65 -87
Net Cash From Continuing Operating Activities
-27 -65 -87
Net Income / (Loss) Continuing Operations
-35 -78 -111
Consolidated Net Income / (Loss)
-35 -78 -111
Depreciation Expense
0.11 0.84 1.02
Amortization Expense
-0.08 -3.21 -1.40
Non-Cash Adjustments To Reconcile Net Income
4.92 18 21
Changes in Operating Assets and Liabilities, net
2.65 -2.42 3.50
Net Cash From Investing Activities
-79 -170 -187
Net Cash From Continuing Investing Activities
-79 -170 -187
Purchase of Property, Plant & Equipment
-1.64 -2.41 -0.62
Purchase of Investments
-77 -378 -355
Sale and/or Maturity of Investments
0.00 210 168
Net Cash From Financing Activities
145 222 271
Net Cash From Continuing Financing Activities
145 158 271
Repayment of Debt
-0.13 0.00 0.00
Repurchase of Preferred Equity
0.00 0.00 -0.00
Issuance of Debt
0.00 158 269
Issuance of Preferred Equity
145 0.00 0.00
Issuance of Common Equity
0.05 0.00 0.00
Other Financing Activities, net
0.00 0.01 1.35

Quarterly Cash Flow Statements for Rapport Therapeutics

This table details how cash moves in and out of Rapport Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
4.12 36 -71 17 0.80 -2.54 196 -199 25 -14 11
Net Cash From Operating Activities
-18 -16 -16 -14 -20 -25 -17 -25 -13 -41 -42
Net Cash From Continuing Operating Activities
-18 -16 -16 -14 -20 -25 -17 -25 -13 -41 -42
Net Income / (Loss) Continuing Operations
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Consolidated Net Income / (Loss)
-23 -18 -18 -20 -24 -27 -27 -34 -20 -57 -40
Depreciation Expense
0.15 0.21 0.22 0.26 0.24 0.25 0.26 0.27 0.23 0.21 0.20
Amortization Expense
-0.98 -0.83 -1.96 0.56 -0.03 -0.50 0.20 -1.07 0.22 0.94 0.26
Non-Cash Adjustments To Reconcile Net Income
9.04 2.51 3.34 3.37 4.04 5.28 5.30 6.26 6.96 7.20 7.63
Changes in Operating Assets and Liabilities, net
-3.16 -0.12 -0.48 1.34 -0.43 -3.37 3.70 3.61 -0.77 6.81 -9.47
Net Cash From Investing Activities
-42 -107 -53 32 21 23 -57 -174 38 26 51
Net Cash From Continuing Investing Activities
-42 -107 -53 32 21 23 -57 -174 38 26 51
Purchase of Investments
-45 -138 -110 -85 -43 -13 -102 -197 -30 -40 -14
Sale of Property, Plant & Equipment
- - - - - - - - - - 0.21
Sale and/or Maturity of Investments
3.95 32 57 117 65 35 45 23 68 65 65
Net Cash From Financing Activities
64 159 -1.39 0.01 0.01 -0.06 271 0.31 0.53 1.41 1.71
Net Cash From Continuing Financing Activities
64 159 -1.39 0.01 0.01 -0.06 271 0.31 0.54 1.41 1.71
Repayment of Debt
-0.28 0.28 - - 0.00 -0.06 0.06 - -0.27 -0.18 0.00
Other Financing Activities, net
0.00 - - - 0.01 - 270 -269 0.81 1.59 1.71

Annual Balance Sheets for Rapport Therapeutics

This table presents Rapport Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
155 315 512
Total Current Assets
151 310 499
Cash & Equivalents
70 57 53
Restricted Cash
0.09 0.11 0.11
Short-Term Investments
77 248 438
Accounts Receivable
- - 0.00
Prepaid Expenses
3.31 4.42 7.92
Plant, Property, & Equipment, net
1.92 3.53 2.98
Total Noncurrent Assets
2.64 1.60 11
Other Noncurrent Operating Assets
2.64 1.60 11
Total Liabilities & Shareholders' Equity
155 315 512
Total Liabilities
14 9.51 28
Total Current Liabilities
8.80 8.77 19
Accounts Payable
2.50 1.95 4.19
Accrued Expenses
5.63 6.08 12
Other Current Liabilities
0.67 0.74 2.76
Total Noncurrent Liabilities
5.68 0.74 8.73
Other Noncurrent Operating Liabilities
5.68 0.74 8.73
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-26 305 485
Total Preferred & Common Equity
-26 305 485
Preferred Stock
- 0.00 0.00
Total Common Equity
-26 305 485
Common Stock
20 430 719
Retained Earnings
-45 -124 -235
Accumulated Other Comprehensive Income / (Loss)
0.00 -0.52 0.55

Quarterly Balance Sheets for Rapport Therapeutics

This table presents Rapport Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
346 331 302 285 535 498 459 419
Total Current Assets
341 326 291 270 521 485 447 407
Cash & Equivalents
110 39 58 55 251 78 64 75
Restricted Cash
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Short-Term Investments
226 281 228 205 262 399 372 320
Accounts Receivable
- - - - - 0.06 0.29 0.17
Prepaid Expenses
4.42 5.17 5.48 9.69 7.53 7.75 10 12
Plant, Property, & Equipment, net
3.47 3.41 3.40 3.17 3.12 2.52 2.34 1.96
Total Noncurrent Assets
1.96 1.80 7.68 12 12 10 9.79 9.22
Other Noncurrent Operating Assets
1.96 1.80 7.68 12 12 10 9.79 9.22
Total Liabilities & Shareholders' Equity
346 331 302 285 535 498 459 419
Total Liabilities
9.21 8.03 16 22 24 26 36 27
Total Current Liabilities
8.10 7.10 9.38 12 14 18 28 20
Accounts Payable
1.88 1.32 2.14 3.18 3.24 6.56 2.80 1.72
Accrued Expenses
5.52 5.06 6.24 6.94 8.60 8.72 23 16
Other Current Liabilities
0.70 0.72 1.01 1.76 2.48 2.62 2.47 2.33
Total Noncurrent Liabilities
1.12 0.93 6.83 10 9.39 8.19 7.63 7.07
Other Noncurrent Operating Liabilities
1.12 0.93 6.83 10 9.39 8.19 7.63 7.07
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
337 323 286 264 512 472 423 391
Total Preferred & Common Equity
337 323 286 264 512 472 423 391
Preferred Stock
0.00 - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity
337 323 286 264 512 472 423 391
Common Stock
423 426 434 438 713 727 736 745
Retained Earnings
-86 -104 -148 -175 -201 -255 -312 -352
Accumulated Other Comprehensive Income / (Loss)
-0.18 0.40 -0.10 -0.08 0.15 -0.51 -1.27 -2.12

Annual Metrics And Ratios for Rapport Therapeutics

This table displays calculated financial ratios and metrics derived from Rapport Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - 47,661,138.00
DEI Adjusted Shares Outstanding
- - 47,661,138.00
DEI Earnings Per Adjusted Shares Outstanding
- - -2.34
Growth Metrics
- - -
Profitability Metrics
- - -
Net Operating Profit after Tax (NOPAT)
-25 -58 -88
Return On Investment Capital (ROIC_SIMPLE)
98.80% -19.04% -18.07%
Earnings before Interest and Taxes (EBIT)
-37 -90 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-37 -93 -125
Valuation Ratios
- - -
Leverage & Solvency
- - -
Liquidity Ratios
- - -
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -65 -82
Efficiency Ratios
- - -
Capital & Investment Metrics
- - -
Invested Capital
-6.62 0.04 -5.99
Increase / (Decrease) in Invested Capital
0.00 6.66 -6.03
Book Value per Share
($17.02) $8.35 $10.17
Tangible Book Value per Share
($17.02) $8.35 $10.17
Total Capital
141 305 485
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-148 -305 -491
Capital Expenditures (CapEx)
1.64 2.41 0.62
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.49 -4.35 -11
Debt-free Net Working Capital (DFNWC)
142 301 480
Net Working Capital (NWC)
142 301 480
Net Nonoperating Expense (NNE)
9.46 20 24
Net Nonoperating Obligations (NNO)
-148 -305 -491
Total Depreciation and Amortization (D&A)
0.04 -2.37 -0.38
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($3.78) ($2.86)
Adjusted Weighted Average Basic Shares Outstanding
0.00 20.74M 38.93M
Adjusted Diluted Earnings per Share
$0.00 ($3.78) ($2.86)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 20.74M 38.93M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 36.50M 47.79M
Normalized Net Operating Profit after Tax (NOPAT)
-25 -58 -88
Debt Service Ratios
- - -
Payout Ratios
- - -

Quarterly Metrics And Ratios for Rapport Therapeutics

This table displays calculated financial ratios and metrics derived from Rapport Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
0.00 - - 36,576,457.00 36,496,437.00 36,497,555.00 36,497,920.00 47,661,138.00 47,792,943.00 47,826,929.00 47,978,286.00
DEI Adjusted Shares Outstanding
0.00 - - 36,576,457.00 36,496,437.00 36,497,555.00 36,497,920.00 47,661,138.00 47,792,943.00 47,826,929.00 47,978,286.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 - - -0.55 -0.65 -0.73 -0.74 -0.72 -0.42 -1.18 -0.84
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -213.73% -145.10% - -6.24% -38.87% -26.26% - 11.60% -106.75% -43.43%
EBIT Growth
0.00% -213.73% -126.27% - -10.72% -41.81% -38.57% - 10.67% -106.15% -47.02%
NOPAT Growth
0.00% -213.73% -126.27% - -58.58% -41.81% -38.57% - 10.67% -106.15% -47.02%
Net Income Growth
0.00% -182.65% -101.37% - -6.15% -47.52% -53.53% - 17.48% -111.79% -49.43%
EPS Growth
0.00% 61.80% 91.23% - 93.86% 55.88% -42.00% - 38.24% -58.67% -18.31%
Operating Cash Flow Growth
0.00% 0.00% -202.64% - -14.89% -53.31% -6.40% - 35.46% -65.36% -138.38%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% - 0.00% -51.07% 2.10% - 41.91% -14.73% -65.98%
Invested Capital Growth
0.00% 0.00% 0.00% - 0.00% 361.06% -164.48% - -1,640.11% -547.84% -160.50%
Revenue Q/Q Growth
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% -100.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -12.43% - 0.00% -10.63% 0.74% - 39.54% -150.96% 26.86%
EBIT Q/Q Growth
0.00% 0.00% -4.04% - 0.00% -8.81% -1.66% - 37.12% -151.11% 27.50%
NOPAT Q/Q Growth
0.00% 0.00% -4.04% - 0.00% -8.81% -1.66% - 37.12% -151.11% 27.50%
Net Income Q/Q Growth
0.00% 0.00% 3.22% - 0.00% -11.09% -0.72% - 41.19% -185.11% 28.93%
EPS Q/Q Growth
0.00% 0.00% 70.59% - 0.00% -10.29% 5.33% - 41.67% -183.33% 29.41%
Operating Cash Flow Q/Q Growth
-70.08% 0.00% 0.00% - -40.09% -23.88% 30.34% - 47.12% -217.40% -0.43%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -15.09% - 0.00% -18.84% 25.42% - 46.34% -134.70% -7.90%
Invested Capital Q/Q Growth
0.00% 0.00% 265.73% - 0.00% 748.14% -151.15% - 10.28% -146.62% 70.25%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 100.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -118.85% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -121.08% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -121.08% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -99.29% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% - 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
92.59% 87.12% 81.04% - 88.77% 90.63% 89.79% - 82.00% 93.11% 91.26%
Effective Tax Rate
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% 0.00% - -27.88% -29.42% -23.41% - -28.33% -39.96% -33.33%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -6.06% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -4.97% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% - -27.88% -29.42% -23.41% - -28.33% -39.96% -33.33%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% - -27.88% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-12 -15 -15 -16 -19 -21 -21 -27 -17 -43 -31
NOPAT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -84.75% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -2.12% -1.49% - -3.56% -2.04% -1.42% - -0.76% -4.03% -2.06%
Return On Investment Capital (ROIC_SIMPLE)
- - - -5.39% -6.64% -7.84% -4.10% -5.56% -3.59% -10.06% -7.89%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 57.50% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 163.58% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 221.08% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-24 -21 -22 -24 -27 -29 -30 -39 -24 -61 -44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-25 -21 -23 -23 -27 -30 -30 -39 -24 -60 -44
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.55 2.32 - 1.28 1.57 2.12 - 3.17 4.71 4.12
Price to Tangible Book Value (P/TBV)
0.00 0.55 2.32 - 1.28 1.57 2.12 - 3.17 4.71 4.12
Price to Revenue (P/Rev)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 74.77 99.65 80.60
Price to Earnings (P/E)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 182.42 - 230.87 52.17 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 50.93 77.84 60.85
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
0.00 -1.00 -0.99 - -1.00 -0.99 -1.00 - -1.01 -1.02 -1.01
Leverage Ratio
0.00 1.03 1.02 - 1.06 1.05 1.04 - 1.06 1.08 1.06
Compound Leverage Factor
0.00 0.90 0.83 - 0.94 0.95 0.93 - 0.87 1.01 0.96
Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 100.00% 100.00% - 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 - 13.68 11.22 27.86 - 34.69 32.91 34.97
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 42.08 45.91 - 31.01 22.75 36.37 - 27.08 15.72 20.07
Quick Ratio
0.00 41.52 45.17 - 30.41 21.93 35.84 - 26.64 15.35 19.47
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -15 -17 0.00 -19 -23 -17 -21 -11 -26 -28
Operating Cash Flow to CapEx
-1,643.19% 0.00% -11,725.00% - -6,954.30% -113,954.55% -13,033.58% - -15,187.21% -53,147.44% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.05 0.05 0.04
Accounts Receivable Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 6.75 7.26 7.88
Accounts Payable Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 0.64 2.35 0.04 0.35 2.96 -1.51 -5.99 -5.38 -13 -3.94
Invested Capital Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - -7.96 -3.89 -7.33
Increase / (Decrease) in Invested Capital
0.00 0.64 2.35 0.00 0.35 2.32 -3.86 -6.03 -5.72 -16 -2.43
Enterprise Value (EV)
0.00 -150 428 - 81 154 571 - 1,019 1,557 1,217
Market Capitalization
136 186 749 - 366 415 1,084 - 1,495 1,993 1,612
Book Value per Share
$0.00 $31.58 $8.83 $8.35 $7.83 $7.22 $14.02 $10.17 $9.87 $8.84 $8.15
Tangible Book Value per Share
$0.00 $31.58 $8.83 $8.35 $7.83 $7.22 $14.02 $10.17 $9.87 $8.84 $8.15
Total Capital
0.00 337 323 305 286 264 512 485 472 423 391
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -336 -321 -305 -285 -261 -513 -491 -477 -436 -395
Capital Expenditures (CapEx)
1.07 0.00 0.14 0.23 0.29 0.02 0.13 0.17 0.09 0.08 -0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -3.67 -1.93 -4.35 -3.90 -2.19 -6.79 -11 -10 -18 -8.06
Debt-free Net Working Capital (DFNWC)
0.00 333 319 301 282 258 506 480 467 418 387
Net Working Capital (NWC)
0.00 333 319 301 282 258 506 480 467 418 387
Net Nonoperating Expense (NNE)
11 3.56 2.39 3.52 5.09 6.08 5.93 6.81 2.91 14 9.37
Net Nonoperating Obligations (NNO)
0.00 -336 -321 -305 -285 -261 -513 -491 -477 -436 -395
Total Depreciation and Amortization (D&A)
-0.83 0.00 -1.75 0.82 0.22 -0.25 0.46 -0.81 0.45 1.15 0.46
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -50.45% -88.75% -40.28%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 2,333.99% 2,092.16% 1,935.40%
Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 2,333.99% 2,092.16% 1,935.40%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.70) ($0.50) $9.49 ($0.68) ($0.75) ($0.71) ($0.72) ($0.42) ($1.19) ($0.84)
Adjusted Weighted Average Basic Shares Outstanding
0.00 10.67M 34.86M 20.74M 35.27M 35.44M 37.93M 38.93M 47.24M 47.47M 47.77M
Adjusted Diluted Earnings per Share
$0.00 ($1.70) ($0.50) $9.49 ($0.68) ($0.75) ($0.71) ($0.72) ($0.42) ($1.19) ($0.84)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 10.67M 34.86M 20.74M 35.27M 35.44M 37.93M 38.93M 47.24M 47.47M 47.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 36.58M 36.58M 36.50M 36.50M 36.50M 47.66M 47.79M 47.83M 47.98M 59.28M
Normalized Net Operating Profit after Tax (NOPAT)
-12 -15 -15 -16 -19 -21 -21 -27 -17 -43 -31
Normalized NOPAT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -84.75% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -99.29% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rapport Therapeutics remains a development-stage company with no consistent operating revenue. Revenue was $20.0 million in Q1 2026 but fell to zero in Q2 2026, while the company reported a $56.6 million net loss in Q2. Losses have generally increased as research and development activity has expanded, from $15.5 million in quarterly R&D expense in Q3 2024 to $51.4 million in Q2 2026.

Liquidity is currently the company’s primary financial strength. As of June 30, 2026, Rapport had $63.6 million in cash and equivalents and $372.5 million in short-term investments, or approximately $436.2 million in readily available funds. Total current assets of $446.9 million compared with current liabilities of $28.4 million, indicating substantial short-term financial flexibility. However, cash and equivalents declined by $14.4 million during Q2 2026 after increasing by $25.4 million in Q1.

Cash flow remains heavily dependent on investment activity and external financing. Operating cash outflow increased from $13.1 million in Q1 2026 to $41.5 million in Q2. Positive investing cash flow primarily reflected sales or maturities of short-term investments, while historical financing inflows—including equity and debt transactions—have helped replenish liquidity. At the Q2 operating cash burn rate, the company’s cash and short-term investments represented roughly 10 quarters of coverage before considering changes in spending, investment income, financing, or clinical-development costs.

  • Large liquidity position: Cash and short-term investments totaled approximately $436.2 million at the end of Q2 2026, providing funding for ongoing research and clinical programs.
  • Strong balance-sheet liquidity: Current assets were nearly 16 times current liabilities, and total liabilities of $36.1 million remained modest relative to total assets of $459.0 million.
  • Investment income provides some support: Interest and investment income contributed $4.2 million in Q2 2026 and has partially offset operating losses in recent quarters.
  • Research spending is being maintained: R&D expense rose to $51.4 million in Q2 2026 from $32.7 million in Q1, potentially reflecting increased investment in the company’s pipeline and development programs.
  • Investment portfolio activity is significant: Q2 investing cash flow was positive $25.6 million because $65.2 million of investments were sold or matured versus $39.7 million of purchases. This improved cash flow but does not represent operating profitability.
  • Q1 revenue appears nonrecurring or inconsistent: Rapport recorded $20.0 million of revenue in Q1 2026 but no revenue in Q2. Investors should determine whether the Q1 amount was a milestone, collaboration payment, or other one-time item.
  • Reported figures include restatements and calculated statements: Several historical income and cash-flow statements are marked as restated or calculated, so quarter-to-quarter comparisons should be reviewed against the company’s latest filings.
  • Operating losses are widening: The Q2 2026 net loss of $56.6 million was substantially larger than the $19.9 million loss in Q1 and the $33.8 million loss in Q4 2025.
  • Operating cash burn accelerated: Net cash used in operating activities increased to $41.5 million in Q2 2026 from $13.1 million in Q1, reducing liquidity despite the company’s sizable investment portfolio.
  • Shareholder dilution is a continuing risk: Weighted-average basic shares increased from approximately 2.0 million in Q1 2024 to 47.5 million in Q2 2026, while common stock on the balance sheet rose substantially as the company relied on equity financing.
11/18/26 09:43 AM ETAI Generated. May Contain Errors.

Rapport Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rapport Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Rapport Therapeutics' net income appears to be on a downward trend, with a most recent value of -$111.48 million in 2025, falling from -$34.79 million in 2023. The previous period was -$78.31 million in 2024. See where experts think Rapport Therapeutics is headed by visiting Rapport Therapeutics' forecast page.

Rapport Therapeutics' total operating income in 2025 was -$125.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $125.10 million

Over the last 2 years, Rapport Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 9 quarters, Rapport Therapeutics' cash and equivalents has ranged from $39.31 million in Q3 2024 to $251.36 million in Q3 2025, and is currently $74.75 million as of their latest financial filing in Q3 2026.

Rapport Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Rapport Therapeutics' book value per share changed from -17.02 in 2023 to 10.17 in 2025.



Financial statements for NASDAQ:RAPP last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners